Carbylan Therapeutics (CBYL) Tops Q3 EPS by 7c

Carbylan Therapeutics (NASDAQ: CBYL) reported Q3 EPS of ($0.19), $0.07 better than the analyst estimate of ($0.26).

For earnings history and earnings-related data on Carbylan Therapeutics (CBYL) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• Kodiak Sciences Inc. (KOD) Misses Q2 EPS by 7c
• KULR Technology Group (KULR) Misses Q2 EPS by 39c